


Tividenofusp Alfa Treatment in a Male Sibling Pair with Non-Neuronopathic Mucopolysaccharidosis Type II

Irene J Chang, Jacqueline Madden, Annie Sako, Jill Dwyer, Daniel Fertek, Adam Scheller, Sharon O'Byrne, Imanol Zubizarreta Arambarri, Peter Chin, Paul Harmatz

Figure S1. Phase 1/2 study design



^aLast time point with available study data for these patients (October 2024 interim data cut).

From *New Engl J Med*, Muenzer J *et al.*, An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II, Vol. 394, pp. 39–50. Copyright © 2026 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Appears as Figure 1A in the original article.

ABBREVIATIONS

6MWT, 6-minute walk test; CSF, cerebrospinal fluid; DS, dermatan sulfate; HS, heparan sulfate; JROM, joint range of motion; KABC-II, Kaufman Assessment Battery for Children, Second Edition; NfL, neurofilament light chain

Tividenofusp alfa (DNL310) is an investigational drug and has not been approved by any health authority. Denali Therapeutics Inc. All rights reserved 2026.